| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Methicillin-resistant Staphylococcus aureus ATCC 43300, typical strain Staphylococcus aureus DSM 20231, Escherichia coli DSM 30083, Acinetobacter baumannii DSM 30007, and Candida albicans DSM 1386 all had equivalent minimum inhibitory concentrations (MICs) for allicin (32–64 μg/mL)[1].
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
DADSO is a known human metabolite of diallyl disulfide. |
| References |
|
| Additional Infomation |
Allicin is a sulfoxide and a botanical anti-fungal agent. It has a role as an antibacterial agent.
Allicin has been used in trials studying the treatment of Follicular Lymphoma. Allicin has been reported in Allium ursinum, Allium ampeloprasum, and other organisms with data available. See also: Garlic (part of). |
| Molecular Formula |
C6H10OS2
|
|---|---|
| Molecular Weight |
162.26
|
| Exact Mass |
162.017
|
| CAS # |
539-86-6
|
| PubChem CID |
65036
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
248.6±43.0 °C at 760 mmHg
|
| Melting Point |
25°C
|
| Flash Point |
104.2±28.2 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.567
|
| LogP |
1.19
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
9
|
| Complexity |
120
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCS(SCC=C)=O
|
| InChi Key |
JDLKFOPOAOFWQN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2
|
| Chemical Name |
3-prop-2-enylsulfinylsulfanylprop-1-ene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~616.26 mM)
Ethanol : ~70 mg/mL (~431.38 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (21.57 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (21.57 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (21.57 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 3.25 mg/mL (20.03 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 3.25 mg/mL (20.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 3.25 mg/mL (20.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1629 mL | 30.8147 mL | 61.6295 mL | |
| 5 mM | 1.2326 mL | 6.1629 mL | 12.3259 mL | |
| 10 mM | 0.6163 mL | 3.0815 mL | 6.1629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00874666 | Unknown status | Other: crushed garlic clove Dietary Supplement: garlic powder tablet |
Healthy | Silliker, Inc. | 2009-04 | Early Phase 1 |
| NCT04545879 | Completed | Dietary Supplement: Raw garlic juice containing allicin | Atherosclerosis | National Taiwan University Hospital | 2019-03-18 | Not Applicable |
| NCT00200785 | Completed | Dietary Supplement: garlic powder added to ambient water Dietary Supplement: garlic powder added to boiling water |
Arteriosclerosis Intracranial Arteriosclerosis |
National Center for Complementary and Integrative Health (NCCIH) | 2006-03 | Not Applicable |
| NCT00029250 | Withdrawn | Drug: Garlic powder standardized to allicin | HIV Infections Hypercholesterolemia Hyperglycemia Hypertriglyceridemia |
National Center for Complementary and Integrative Health (NCCIH) | 2001-11 | Phase 2 |
| NCT00122889 | Completed | Drug: Garlic powder with high allicin content
Drug: Garlic powder with low allicin content Drug: Garlic oil Drug: Aged garlic |
Healthy | Fred Hutchinson Cancer Center | 2005-07 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
